PHOSPHOMANNOMUTASE II CONGENITAL DISORDER OF GLYCOSYLATION

Clinical trials for PHOSPHOMANNOMUTASE II CONGENITAL DISORDER OF GLYCOSYLATION explained in plain language.

Never miss a new study

Get alerted when new PHOSPHOMANNOMUTASE II CONGENITAL DISORDER OF GLYCOSYLATION trials appear

Sign up with your email to follow new studies for PHOSPHOMANNOMUTASE II CONGENITAL DISORDER OF GLYCOSYLATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Promising PMM2-CDG drug trial halted early

Disease control Terminated

This study tested an oral drug called epalrestat in children aged 2 to 17 with PMM2-CDG, a rare genetic disorder that affects how the body makes certain proteins. The goal was to see if the drug could improve symptoms and lab markers compared to a placebo. The trial was terminate…

Matched conditions: PHOSPHOMANNOMUTASE II CONGENITAL DISORDER OF GLYCOSYLATION

Phase: PHASE3 • Sponsor: Maggie's Pearl, LLC • Aim: Disease control

Last updated Apr 24, 2026 16:05 UTC

PHOSPHOMANNOMUTASE II CONGENITAL DISORDER OF GLYCOSYLATION

Get alerted when new PHOSPHOMANNOMUTASE II CONGENITAL DISORDER OF GLYCOSYLATION trials appear

Promising PMM2-CDG drug trial halted early